U.S. FDA Issues Warning Letter To Sun Pharma, Questions Manufacturing Practices At Halol Facility

The US Food and Drug Administration (FDA) has slammed Sun Pharma, the country’s largest generic drug maker, for manufacturing violations such as failure to investigate discrepancies in batches of products, not cleaning equipment used in drug manufacturing and failing to prevent contamination at its Halol facility in Gujarat.In a warning letter, the FDA has highlighted a series of lapses at Sun Pharma’s Gujarat plant, which has been put on an import alert list by the US drug regulator.#sunpharma #halolfacility #usfda #cnbctv18 #businessnews #businessnewstoday #businessnewsinenglish #sharemarkettoday About CNBC-TV18: